Dr peter carroll san francisco
Home / Health, Lifestyle & Body Facts / Dr peter carroll san francisco
John Lindsey is an Urologist, who primarily practices in Berkeley, CA with 2 additional practice locations. Through his work in research infrastructure development and multidisciplinary care, Dr. Carroll remains a central figure in shaping the direction of prostate cancer management worldwide.
Dr. Dr. Carroll then displays a pictogram of what he calls “the Achilles heel of PSA screening.” It shows that among 1,000 men in the US, about 250 have an elevated PSA.
If all patients with elevated PSA are biopsied, the results show that half have no disease and, of the remaining men, about 30-40 percent have low-risk disease. Michael Disandro, MD is a Pediatric Urologist, who primarily practices in Oakland, CA with 2 additional practice locations. He asserts that recent studies suggest that upfront biomarker testing with conditional MRI may be the most efficient strategy for early detection, with cost and availability being strong considerations.
Louis Select Choice POS II (MO,IL)
St. Dr. Carroll concludes that DRE could not be implemented effectively in a nationwide screening program.
His academic impact is reflected in numerous awards and lectureships, and his expertise continues to influence surgical practice, translational science, and health outcomes in urologic oncology.
Is Dr. Carroll board certified in Urologist?
Yes, Dr. Peter Carroll, MD is board certified by the American Board of Urology
What conditions does Dr.
Carroll treat?
As a Urologist, Dr. Carroll diagnoses, treats, and manages a wide range of conditions. He highlights the recommendation that digital rectal examination (DRE) should be used as a complement to PSA testing, not as a standalone screening test. He supports this assertion with data on various biomarker tests as well as early detection algorithms.
He is board certified.
Berkeley, CA
Dr. Peter R. Carroll, MD, MPH, is a prominent academic urologic oncologist whose work has fundamentally shaped the clinical and scientific understanding of prostate cancer. He is board certified.
Berkeley, CA
Dr.
Dr. Carroll then cites data from a recent trial in the NEJM showing that MRI-targeted biopsy decreases the likelihood of negative or benign biopsy and testing with biomarkers can reduce biopsies by 20-65 percent while missing few (2.5-8 percent) high-grade cancers. Louis Select Open Access Elect Choice (MO)
St.
His scholarly output includes over 650 peer-reviewed publications, and his research has played a significant role in the refinement of clinical guidelines and surveillance-based management strategies for prostate cancer.
In addition to his research and institutional leadership, Dr. Carroll has held leadership roles in multiple national and international organizations in urology and oncology.
Louis Select Open Access Aetna Select (MO)
St. Carroll is internationally recognized for his contributions to prostate cancer outcomes research, particularly in the areas of active surveillance, biomarker development, and risk stratification. He emphasizes that data show that the number of patients screened and diagnosed to avoid one death improves significantly over time and thus it is important to recognize the long-term impact of screening.
However, he explains that a decision not to biopsy requires use of a biomarker test along with MRI, since the negative predictive value (NPV) of MRI is 85 percent.